Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Basilard BioTech, a Southern California biotechnology company pioneering novel delivery technologies for cell and gene therapy, announced a strategic collaboration to accelerate the development and translation of Basilard BioTech’s nanomechanical gene delivery platform, Celletto.
Celletto addresses long-standing limitations of both viral vectors and conventional non-viral methods. By creating a controlled, transient disruption to the cell membrane using nanoneedles to directly transport nucleic acids (or any construct) into the nucleus of any cell type each time, Celletto enables exceptionally high transfection efficiency while preserving cell viability and function.
“Our partnership with Basilard BioTech opens up an exceptional pathway to bring next-generation gene delivery into mainstream manufacturing,” said Syed T. Husain, chairman and CEO of Made Scientific. “By pairing Basilard’s Celletto platform with Made Scientific’s end-to-end clinical and commercial CDMO services, we can provide biotech innovators with a more scalable, efficient and commercially viable solution for advancing transformative T cell and iPSC therapies.”
Under the agreement, Basilard BioTech will leverage Made Scientific’s Center of Excellence for Process and Analytical Development and its state-of-the-art GMP manufacturing facility in Princeton to validate and scale the Celletto platform across T cell, iPSC processes and other cell substrates in the future.
“We look forward to collaborating with Made Scientific to demonstrate the transformative and disruptive potential of Celletto,” said Brynley Lee, founder, president and CEO of Basilard BioTech. “Our goal is to create a gene delivery solution that works seamlessly with all cell types, preserves cell health, drives reproducible gene transfer and scales seamlessly from research to GMP production, ultimately accelerating the path to safer, more effective therapies. Made Scientific, with their deep experience and skilled teams, is the perfect partner for helping to confirm Celletto’s unique capabilities.”
On-site installation, training and execution of joint studies is underway, with initial data readouts expected by the end of Q3 2025, and publication of results and presentation at upcoming industry conferences.
